LexaGene Announces the Completion of its Previously Announced Reverse Takeover Transaction

LexaGene is pleased to announce the completion of its previously announced reverse takeover transaction (the “RTO”) pursuant to which it acquired Bionomics Diagnostics Inc. (“BDI”). The Company’s common shares will commence trading on the TSX Venture Exchange (the “TSXV”) as a Tier 2 technology issuer under the symbol “LXG” once the TSXV’s conditions for listing are satisfied and the TSXV issues its final exchange bulletin confirming the completion of the RTO.


For Media Inquiries Contact

Gail Winslow

Director, Marketing

978 - 482 - 6237